July 6, 2018

Please reload

Recent Posts

FDA Comments on Recently Released Rare Disease Guidance for Industry

September 16, 2015

Jonathan Goldsmith, M.D., F.A.C.P., FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research, comments on the recently...

Please reload

Featured Posts

Patagonia Enters into Global Licensing Agreement with Almirall for PAT-001

July 22, 2016

Patagonia is excited to announce that we have entered into a global licensing agreement with Almirall for our lead product, PAT-001.  Almirall and Patagonia Pharmaceuticals will jointly conduct development activities of Patagonia's lead product (PAT-001). Almirall will acquire global commercialization rights for such product and others that could be developed based on existing related Patagonia intellectual property.


For more information, please visit: http://www.almirall.com/en/media/press-releases/media-detail-new?title=almirall-announces-a-global-licensing-agreement-with-patagonia-for-congenital-ichthyosis&articleId=362072

Please reload

Patagonia Pharmaceuticals, LLC

50 Tice Blvd, Suite A26

Woodcliff Lake, NJ 07677

For more info: info@patagoniarx.com

© 2019 by Patagonia Pharmaceuticals, LLC